“Resume sales of Nabota in the US… Leading the recovery of K-bio’s public confidence in efforts to clarify the truth of the Korean lawsuit”
In connection with the announcement that Evolus, AbbVie, and Medytox have signed a three-way agreement on the 19th, Daewoong Pharmaceutical said on the 20th, “This contract is the US International Trade Commission for the sale of Daewoong Pharmaceutical’s botulinum toxin’Jeuveau’ ITC) It is known that it is for settlement of lawsuits, and Daewoong Pharmaceutical is not a party to this agreement and has never agreed in advance.” It was judged to be a decision made entirely on the basis of management judgment to avoid interruption, and as the ITC’s application for urgent provisional injunction against the 21-month income ban was cited and the appeal proceeded, AbbVie and Medytox had created a case of lawsuit against them. It is analyzed that it has been urgently agreed with Ebolus to judge.”
Also, “Daewoong Pharmaceutical filed an appeal to the US Federal Circuit Court of Appeal (CAFC) through expedited procedures, and since they were convinced that Medytox’s allegations were all false and would win, there was no reason to agree with Abbe and Medytox. Therefore, we regret that there is no opportunity to correct errors in ITC decisions based on this agreement.”
Daewoong Pharmaceutical said, “However, due to the agreement, risks in the US business have been completely resolved and the basis for resumption of Nabota sales has been laid,” said Daewoong Pharmaceutical. “Based on Nabota’s advanced quality and technology, Daewoong Pharm. With plans to accelerate the market penetration, Nabota’s global sales and profits are also expected to increase dramatically.”
In addition, “We will continue our efforts to clarify the truth about the numerous unfounded claims of Medytox that have been revealed so far, and we are confident that we will win the domestic civil and criminal trials in the near future.” In order to restore public confidence in’K-bio’ which has been deteriorated, we will take the lead in developing innovative technologies and improving quality, and will do our best to improve the public’s convenience by providing safe and excellent quality medicines.”
Copyright © Farm News Unauthorized reproduction and redistribution prohibited